BioSpace News Archive

Biotech Bay

Nevro Delivers Long-Term Relief with High-Frequency Spinal Cord Stimulation: 24-Month Data Demonstrates Profound Improvements for Non-Surgical Refractory Back Pain

Nevro Corp. today announced the publication of new 24-month data from the SENZA Nonsurgical Refractory Back Pain (NSRBP) multicenter randomized controlled trial (RCT) in the Journal of Neurosurgery: Spine.

November 20, 2023
·
7 min read
Satellos to Present at the Piper Sandler 35th Annual Healthcare Conference

Satellos Bioscience Inc. announced today that management will present and participate in the Piper Sandler 35th Annual Healthcare Conference taking place November 28-30 in New York City.

November 20, 2023
·
1 min read
IRLAB to Present at ABGSC Investor Days on November 22, 2023

IRLAB Therapeutics AB announced that the company will present at the ABGSC Investor Days on Wednesday, November 22, 2023, in Stockholm, Sweden.

November 20, 2023
·
1 min read
Lecanemab winner in two categories at The Scrip Awards 2023

BioArctic AB’s invention lecanemab, partnered with Eisai, was awarded the Best New Drug and the award for the Clinical Advance of the Year at the Scrip Awards 2023.

November 20, 2023
·
3 min read
Drug Development

First Subject Enrolled in Phase 1 Study of MRX-5

Recently, Shanghai MicuRx Pharmaceuticals Co., Ltd. announced that its proprietary antibiotic MRX-5, has enrolled its first subject in the first Phase I clinical trial in Australia.

November 20, 2023
·
1 min read
Business

Prenetics Announces Third Quarter 2023 Financial Results

Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics-driven health sciences company, today announced financial results for the third quarter ended September 30, 2023, along with recent business updates.

November 20, 2023
·
19 min read
Business

Fortrea Announces AI-Driven Partnership with Medidata to Increase Diversity in Clinical Trials

Fortrea today announced a partnership with Medidata to use Medidata AI Intelligent Trials to increase access to diverse patients in clinical trials conducted by Fortrea.

November 20, 2023
·
2 min read
Drug Development

Agios Announces Clinical Proof-of-Concept in Phase 2a Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes

Agios Pharmaceuticals, Inc. today announced that clinical proof-of-concept has been achieved in the Phase 2a portion of a study of investigational pyruvate kinase (PK) activator AG-946 as a potential treatment for anemia in adults with lower-risk myelodysplastic syndromes (LR-MDS).

November 20, 2023
·
8 min read
Biotech Bay

Gritstone bio to Participate in Upcoming Investor Conferences

Gritstone bio, Inc. today announced that management will be participating in the following investor conferences.

November 20, 2023
·
1 min read
Drug Development

ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease

ProMIS Neurosciences Inc. today announced that the Company dosed the first subjects in a first-in-human Phase 1a clinical trial of PMN310 as a potential treatment for Alzheimer’s disease (AD).

November 20, 2023
·
6 min read